National Bank of Canada FI Sells 1,688 Shares of Qiagen (NYSE:QGEN)

National Bank of Canada FI reduced its position in Qiagen (NYSE:QGEN) by 6.2% in the second quarter, HoldingsChannel.com reports. The firm owned 25,328 shares of the company’s stock after selling 1,688 shares during the period. National Bank of Canada FI’s holdings in Qiagen were worth $1,028,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. CWM LLC boosted its stake in shares of Qiagen by 12.0% in the second quarter. CWM LLC now owns 2,505 shares of the company’s stock worth $103,000 after acquiring an additional 269 shares during the period. Eagle Asset Management Inc. increased its holdings in shares of Qiagen by 2.2% in the fourth quarter. Eagle Asset Management Inc. now owns 20,338 shares of the company’s stock worth $883,000 after purchasing an additional 430 shares during the last quarter. TD Asset Management Inc boosted its position in shares of Qiagen by 1.0% during the 4th quarter. TD Asset Management Inc now owns 53,531 shares of the company’s stock valued at $2,330,000 after acquiring an additional 554 shares during the last quarter. Riverview Trust Co purchased a new position in shares of Qiagen in the first quarter valued at $28,000. Finally, Park Place Capital Corp bought a new stake in Qiagen in the first quarter worth $36,000. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Trading Down 0.6 %

Shares of NYSE QGEN opened at $45.57 on Friday. Qiagen has a twelve month low of $34.74 and a twelve month high of $47.44. The business has a fifty day simple moving average of $44.25 and a two-hundred day simple moving average of $43.36. The firm has a market cap of $10.40 billion, a PE ratio of 30.58, a price-to-earnings-growth ratio of 3.17 and a beta of 0.39. The company has a quick ratio of 1.46, a current ratio of 1.77 and a debt-to-equity ratio of 0.27.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.52 by $0.03. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The business had revenue of $496.00 million during the quarter, compared to analyst estimates of $495.45 million. During the same quarter in the previous year, the business posted $0.53 EPS. The company’s quarterly revenue was down .2% compared to the same quarter last year. Analysts expect that Qiagen will post 2.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on QGEN shares. Wolfe Research upgraded shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price objective for the company in a research report on Thursday, June 27th. JPMorgan Chase & Co. lifted their price target on shares of Qiagen from $52.00 to $54.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 18th. Finally, Robert W. Baird boosted their price objective on Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $51.10.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.